[Metastatic cancer in transposed ovaries after radical Wertheim-Meigs hysterectomy for a stage I B and II A cervical cancer].
In this research work we show our and foreign experience in preserving the ovarian function in young women and cervical cancer stage I B and II A. 6 cases are quoted for the period of time from 1987 till 2003 (4 patients with ovarian metastases from our experience and 2 patients with ovarian metastases found from the greek colleagues). Histologically 3 patients were with adenosquamous metastatic cervical cancers and 3 patients with squamous metastatic cervical cancers in the region of the transposed ovaries. The metastases occurred mostly 2 to 3 years after the radical hysterectomies a modo Wertheim-Meigs. Nevertheless our experience which is connected with radical hysterectomies a modeo W. Meigs including both ovaries, we have also experience in transposing ovaries /one or both of them/. In some of them we found metastases. In our research work we found 4 cases with metastases in transposed ovaries. In these cases a chemotherapy was applied: mitomicin C, etoposide, and cysplatinum. The greek colleagues also have applied such schemes of chemotherapy. 3 from the patients had a very good effect from the chemotherapy, in 2 the recurrences have appeared 2 years after the chemotherapy, and in one case there was a very big progression of the disease, nevertheless the chemotherapy. IT is very important for the oncogynaecologist to clear up if the transposition of the ovaries is safe and effective, especially in young patients with early cervical cancer receiving postoperative radiotherapy. That is why we did this research work in order to give more light on this problem.
Ivanov
S
S
Zervoudis
S
S
Ivanov
S
S
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018196:Carcinoma, Adenosquamous / Q000188:drug therapy / Q000556:secondary*; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000379:methods*; D016685:Mitomycin / Q000008:administration & dosage; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000556:secondary*; D010053:Ovary / Q000187:drug effects / Q000601:surgery*; D016896:Treatment Outcome; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000601:surgery*
D016685:Mitomycin; D005047:Etoposide; D002945:Cisplatin